Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

ClinicalTrials.gov ID: NCT06672939

Public ClinicalTrials.gov record NCT06672939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral Versus Placebo in Adolescent Participants Who Have Obesity, or Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.

Study identification

NCT ID
NCT06672939
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
150 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 17, 2024
Primary completion
Nov 30, 2027
Completion
Dec 31, 2030
Last update posted
Aug 23, 2026

2024 – 2031

United States locations

U.S. sites
12
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Carey Chronis MD Pediatric, Infant and Adolescent Medicine Oxnard California 93030 Active, not recruiting
Stamford Therapeutics Consortium Stamford Connecticut 06905 Active, not recruiting
Children's Healthcare of Atlanta - Center for Advanced Pediatrics Atlanta Georgia 30329 Active, not recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611 Active, not recruiting
Velocity Clinical Research Lafayette Louisiana 70508 Active, not recruiting
Sundance Clinical Research St Louis Missouri 63141-7068 Active, not recruiting
Lucas Research, Inc. Morehead City North Carolina 28557 Active, not recruiting
Childrens Hospital of Pittsburgh Pittsburgh Pennsylvania 15224 Active, not recruiting
Vanderbilt Health One Hundred Oaks Nashville Tennessee 37212 Active, not recruiting
Dynamed Clinical Research, LP d/b/a DM Clinical Research Houston Texas 77065 Active, not recruiting
La Providence Pediatrics Clinic - Chemidox Clinical Trials Houston Texas 77071-1008 Active, not recruiting
Martin Diagnostic Clinic Tomball Texas 77375-3332 Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06672939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06672939 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →